News
8d
Zacks.com on MSNMRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales ViewModerna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...
Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...
Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
Despite exceeding Street forecasts with its Q2 2025 financials, Moderna (NASDAQ:MRNA) shares fell ~7% in the premarket on ...
6d
Verywell Health on MSNWho Should Get the RSV Vaccine This Year?The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...
The company reported a net loss of $825 million for the quarter. Additionally, Moderna announced a $300 million reduction at the high end of their 2025 projected revenue range due to a timing shift of ...
The company last reported total revenues of $108M in Q1, down 35.3% Y/Y due to lower net product sales, particularly its ...
2d
Barchart on MSNModerna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here?Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...
It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...
Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results